Phase II trial of iodine 131-labeled murine anti-tenascin monoclonal anti-body 81C6 (M81C6) via surgically created resection cavity in the treatment of patients with recurrent malignant brain tumors.


Conference Paper

Full Text

Duke Authors

Cited Authors

  • Badruddoja, MA; Reardon, DA; Akabani, G; Friedman, AH; Friedman, HS; Rich, JN; Quinn, JA; Penne, K; Vredenburgh, JJ; Bigner, DD

Published Date

  • July 15, 2004

Published In

Volume / Issue

  • 22 / 14

Start / End Page

  • 124S - 124S

Published By


  • 1

International Standard Serial Number (ISSN)

  • 0732-183X

Conference Name

  • 40th Annual Meeting of the American-Society-of-Clinical-Oncology

Conference Location

  • New Orleans, LA

Conference Start Date

  • June 5, 2004

Conference End Date

  • June 8, 2004